<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ann Packeu</style></author><author><style face="normal" font="default" size="100%">Jean-Paul De Backer</style></author><author><style face="normal" font="default" size="100%">Isabelle Van Liefde</style></author><author><style face="normal" font="default" size="100%">Patrick M L Vanderheyden</style></author><author><style face="normal" font="default" size="100%">Georges Vauquelin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antagonist-radioligand binding to D2L-receptors in intact cells.</style></title><secondary-title><style face="normal" font="default" size="100%">Biochem Pharmacol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Cho Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Computer Simulation</style></keyword><keyword><style  face="normal" font="default" size="100%">Cricetinae</style></keyword><keyword><style  face="normal" font="default" size="100%">Cricetulus</style></keyword><keyword><style  face="normal" font="default" size="100%">Deuterium</style></keyword><keyword><style  face="normal" font="default" size="100%">Dopamine Antagonists</style></keyword><keyword><style  face="normal" font="default" size="100%">Dopamine D2 Receptor Antagonists</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Ligands</style></keyword><keyword><style  face="normal" font="default" size="100%">Raclopride</style></keyword><keyword><style  face="normal" font="default" size="100%">Radioligand Assay</style></keyword><keyword><style  face="normal" font="default" size="100%">Receptors, Dopamine D2</style></keyword><keyword><style  face="normal" font="default" size="100%">Spiperone</style></keyword><keyword><style  face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008 Jun 01</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">75</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;D(2)-dopamine receptors mediate most of the physiological actions of dopamine and are important recognition sites for antipsychotic drugs. Earlier binding studies were predominantly done with broken cell preparations with the tritiated D(2)-receptor antagonists [(3)H]-raclopride, a hydrophilic benzamide, and [(3)H]-spiperone, a highly hydrophobic butyrophenone. Here we compared [(3)H]-raclopride and [(3)H]-spiperone binding properties in intact Chinese Hamster Ovary cells stably expressing recombinant human D(2L)-receptors. Specific binding of both radioligands occurred to a comparable number of sites. In contrast to the rapid dissociation of [(3)H]-raclopride in both medium only and in the presence of an excess of unlabelled ligand [(3)H]-spiperone dissociation was only observed in the latter condition, and it was still slower than in broken cell preparations. However, this could not explain the pronounced difference in the potency of some unlabelled ligands to compete with both radioligands. To integrate these new findings, a model is proposed in which raclopride approaches the receptor from the aqueous phase, while spiperone approaches the receptor by lateral diffusion within the membrane.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">11</style></issue></record></records></xml>